Sanofi buys US biopharma group Blueprint in $9.1 bln deal

Behind the Headlines, Episode 18: Sanofi, GSK Go Big in M&A, mRNA Momentum Falters, and More

Jon Ellis and Simon Vanstone, PhD, go behind the headlines to explore the latest M&A activity and what tariffs and funding changes could mean for mRNA and beyond.

Sanofi announces major purchase amid pledge to up U.S. investments

Global healthcare company Sanofi, headquartered in Paris, France, is announcing another pricey purchase in the U.S.

Pharmalittle: We're reading about Sanofi buying Blueprint, a Bristol deal with BioNTech and more

Kymera Therapeutics reported that an experimental drug designed to rival Dupixent succeeded in a closely watched early-stage trial

Sanofi to acquire Blueprint for up to $9.5B

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost to its immunology business.

Sanofi to buy US biopharma group Blueprint Medicines for $9.1 Billion equity value

Sanofi will purchase Blueprint Medicines for $9.1 billion to bolster its rare disease portfolio. 

France’s Sanofi to buy U.S. biopharma group Blueprint for up to $9.5-billion

The deal is the largest by a European health care company this year, and is meant to add to Sanofi’s portfolio of drugs for rare immunology diseases